You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Eye conditions

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration

  • Technology appraisal guidance
  • Reference number: TA155
  • Published:  27 August 2008
  • Last updated:  20 May 2024
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Macular degeneration (age-related) - pegaptanib and ranibizumab: appeal announcement

The Institute received 2 appeals from Pfizer and Derbyshire County PCT.

An appeal hearing was held on 30 June 2008.  The Institute awaits the decision of the appeal panel.

  • Macular degeneration (age-related) - pegaptanib and ranizumab: appeal from Derbyshire County PCT 

  • Macular degeneration (age-related) - pegaptanib and ranizumab: appeal from Pfizer


This page was last updated: 30 March 2010

Back to top